Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals.
Subscribe to our email newsletter
Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated.
Generic and brand sales of Retin-A, which is indicated for the topical treatment of acne vulgaris, were approximately $287m for the 12-months ending October 2015. Additional financial terms were not disclosed.
Perrigo chairman and CEO Joseph. Papa said: "We are excited to reacquire this high-barrier to entry product into our unique Rx portfolio. This serves as yet another example of our ability to execute on our ‘Base Plus Plus Plus’ strategy and we believe this margin-enhancing asset superbly complements our already robust Rx portfolio. We remain committed to continue delivering superior value for our shareholders."
The transaction is expected to immediately exceed Perrigo’s ROIC threshold and add more than $0.20 in adjusted EPS within the first 12 months post-close after the exclusion of estimates for intangible amortization, transaction costs and integration related expenses.
The transaction is expected to close in the first quarter of 2016, subject to customary closing conditions.